Rezdiffra (Resmetirom) EMA vs FDA: What Women Need to Know About Approval, Label, and Safety

What Is Rezdiffra and Why Does It Matter for Women?

Rezdiffra is the brand name for resmetirom, a first-in-class selective thyroid hormone receptor beta (THR-beta) agonist made by Madrigal Pharmaceuticals. It targets the liver directly to reduce fat accumulation and fibrotic damage without activating thyroid receptors in the heart or bone, which is where classic thyroid hormone side effects live.

MASH (metabolic dysfunction-associated steatohepatitis, previously called NASH) is not a gender-neutral disease. Women make up roughly 40 to 50 percent of MASH cases globally, and two female-specific conditions, PCOS and the hormonal shift of perimenopause, independently raise the risk. Estrogen loss after menopause accelerates hepatic fat deposition and insulin resistance, making postmenopausal women a distinct high-risk group that often goes unrecognized in liver disease clinics.

Before Rezdiffra, the only treatment options were lifestyle change and, for advanced fibrosis, liver transplant planning. A disease this common in women going decades without an approved drug is a significant gap.

The FDA Approval: What Happened and When

Accelerated Approval Pathway

The FDA granted accelerated approval to Rezdiffra on March 14, 2024, making it the first drug ever approved specifically for MASH with liver fibrosis. The agency used its accelerated approval mechanism, which allows approval based on a surrogate or intermediate clinical endpoint reasonably likely to predict clinical benefit. In this case, that endpoint was a composite of histological response: NASH resolution or fibrosis improvement on liver biopsy at 52 weeks.

This was not a rubber-stamp decision. The FDA's Gastrointestinal Drugs Advisory Committee reviewed the full MAESTRO-NASH data before approval. The accelerated pathway means confirmatory evidence of hard clinical outcomes, meaning reduction in cirrhosis, liver-related death, and liver transplant, must arrive from ongoing trials before full approval is granted.

MAESTRO-NASH: The Trial Behind the Approval

The MAESTRO-NASH trial, published in the New England Journal of Medicine in 2024, was a phase 3, randomized, double-blind, placebo-controlled study in 966 patients with biopsy-confirmed MASH and fibrosis stage F1b through F4. At 52 weeks:

• 26% of patients on 80 mg resmetirom achieved the fibrosis-improvement endpoint versus 14% on placebo.
• 30% of patients on 100 mg achieved fibrosis improvement versus the same 14% placebo rate.
• NASH resolution (no or minimal steatohepatitis without fibrosis worsening) occurred in 30% and 38% of the 80 mg and 100 mg groups respectively, compared with 13% on placebo.

Women made up approximately 52 percent of the MAESTRO-NASH enrollment, which is a better sex-representation figure than most liver disease trials historically achieved. Subgroup data by sex were not separately published as primary endpoints, so whether response rates differ meaningfully between women and men remains an open question. This is an evidence gap that matters, and you deserve to know it exists.

What the FDA Label Says

The prescribing information approved by the FDA specifies:

• Indicated for MASH with moderate to advanced liver fibrosis, corresponding to stages F2 and F3.
• Dosing is weight-based: 80 mg once daily for patients weighing less than 100 kg, and 100 mg once daily for those weighing 100 kg or more.
• Not approved for compensated cirrhosis (F4) as a primary indication; the evidence in that group was insufficient at the time of approval.
• Thyroid function monitoring is required before starting and during treatment.
• The label includes a specific warning about drug interactions with bile acid sequestrants, statins, and drugs that affect thyroid hormone levels.

The EMA's Different Path

Where Europe Stands

The European Medicines Agency had not granted a marketing authorization for resmetirom as of early 2025. The EMA operates under a rolling review procedure, which allows its Committee for Medicinal Products for Human Use (CHMP) to assess data as they become available before a formal marketing authorization application (MAA) is submitted in final form. Madrigal Pharmaceuticals announced the rolling review was underway, but no approval timeline has been confirmed publicly.

The EMA's standard approval pathway requires demonstration of clinical benefit, not just a surrogate endpoint. The EMA generally applies a stricter interpretation of surrogate endpoints for liver disease drugs than the FDA has under accelerated approval, though the agency does have its own conditional marketing authorization mechanism that is conceptually similar.

Why the Timelines Diverged

The FDA moved first for several reasons. Its accelerated approval framework explicitly allows histological surrogates for liver disease. The MAESTRO-NASH data met those thresholds cleanly. The EMA has historically required longer outcome data or at minimum more post-market commitment clarity before granting authorization, particularly for a drug in a therapeutic class with no precedent.

This divergence is not unique to resmetirom. The FDA approved obeticholic acid for primary biliary cholangitis years before European alignment, and similar gaps appeared with elafibranor. The pattern reflects genuinely different philosophies about acceptable uncertainty at first approval, not a difference in the underlying science.

For a woman living in Europe with MASH and fibrosis right now, this gap is not abstract. It means no approved option and likely earlier access only through clinical trials.

A Framework for Understanding FDA vs EMA Regulatory Risk Tolerance in Liver Disease

The two agencies differ on three specific dimensions that matter for MASH drugs:

| Dimension | FDA | EMA | |---|---|---| | Surrogate endpoint acceptance | Histological composite at 52 weeks acceptable for accelerated approval | Requires harder outcome data or conditional authorization with binding post-market requirements | | Post-market commitment enforceability | Accelerated approval can be withdrawn if confirmatory trial fails, but timeline is flexible | Conditional MA carries stricter annual renewal review | | Label language on uncertainty | Often includes "limitations of use" language | Often delays approval until uncertainty is lower |

Neither approach is objectively superior. Women in the US gain earlier access but accept more residual uncertainty about long-term outcomes. Women in Europe wait longer but receive a label backed by more outcome evidence.

Sex-Specific Physiology: How Being a Woman Changes the Picture

Hormonal Overlap With Thyroid Function

Resmetirom works at the thyroid receptor beta, which is expressed predominantly in the liver. This selectivity is the reason the drug does not cause hyperthyroidism systemically. However, thyroid disease is already three to five times more common in women than in men, and thyroid disorders affect 5 to 10 percent of women of reproductive age. If you have treated hypothyroidism and take levothyroxine, resmetirom may alter the pharmacokinetics of thyroid hormone replacement. The FDA label explicitly flags this interaction and recommends monitoring TSH.

PCOS and MASH: A Compound Risk

Women with PCOS have up to a 4-fold higher prevalence of MASH compared with BMI-matched controls, driven by hyperinsulinemia, androgen excess, and visceral adiposity. If you have PCOS and elevated liver enzymes or unexplained hepatic steatosis on ultrasound, MASH should be on your differential before attributing it to something else. Resmetirom is not currently approved specifically for PCOS-related MASH as a distinct indication, but PCOS patients were not excluded from MAESTRO-NASH.

Perimenopause and Postmenopause

Estrogen has a protective effect on hepatic lipid metabolism. Postmenopausal women show a measurable increase in liver fat fraction independent of changes in overall body weight, a phenomenon driven by estrogen withdrawal. This means MASH can emerge or worsen during the menopausal transition even without weight gain, and it often goes undetected because the clinical focus is on hot flashes and bone density rather than liver function.

If you are in perimenopause or postmenopause and your metabolic markers are changing, asking your provider about a liver ultrasound or controlled attenuation parameter measurement is reasonable. Resmetirom targets the downstream hepatic consequences of insulin resistance and dyslipidemia regardless of their hormonal origin.

Reproductive Years: Contraception Is Non-Negotiable

Women of reproductive age taking resmetirom must use effective contraception throughout treatment. This is addressed in detail in the pregnancy section below.

Pregnancy, Lactation, and Contraception

Resmetirom is contraindicated in pregnancy. This applies from the first dose and for a period after stopping treatment, and it must be communicated clearly before any prescription is written.

Pregnancy Data

There are no adequate human data on resmetirom use in pregnancy. Animal reproductive toxicity studies conducted by Madrigal showed fetal harm at doses below the human clinical dose. The FDA label assigns resmetirom a warning against use in pregnancy based on this animal data, and there is no human registry or prospective cohort study to reassure us otherwise at this point.

If a pregnancy occurs during treatment, the drug should be stopped immediately and the patient referred to a maternal-fetal medicine specialist. MASH itself does not typically worsen acutely in pregnancy, but the underlying metabolic conditions (insulin resistance, dyslipidemia) that drive MASH do require active management during gestation through diet, blood glucose control, and close obstetric surveillance.

Contraception Requirements

Any woman of childbearing potential starting resmetirom must use at least one highly effective contraceptive method while on treatment. The label does not specify a washout period for conception after stopping, but given the drug's half-life and animal data, your prescriber should discuss this before you discontinue for family planning purposes. Combined hormonal contraceptives, intrauterine devices, and progestin implants are all reasonable options; the choice should account for your individual metabolic profile, since PCOS or insulin resistance may influence which method you prefer.

Lactation

There are no human data on resmetirom transfer into breast milk. Animal lactation studies have not been published in detail. The FDA label advises against breastfeeding during treatment with resmetirom because of the unknown risk of infant exposure and the potential for harm based on animal findings. Women who are breastfeeding should not take resmetirom. If treatment is medically necessary, a shared decision-making conversation about the timing of weaning is appropriate.

Who This Drug Is Right For (and Who It Is Not)

Women Who May Benefit

• Postmenopausal women with biopsy-confirmed MASH, F2 or F3 fibrosis, and metabolic comorbidities (type 2 diabetes, dyslipidemia, obesity).
• Women with PCOS who have progressed to fibrotic MASH despite lifestyle optimization.
• Women in their reproductive years with F2-F3 MASH who are not pregnant, not planning pregnancy in the near term, and using reliable contraception.
• Women with treated hypothyroidism who have MASH, provided thyroid function is stable and TSH monitoring is built into the follow-up plan.

Women Who Should Not Take Resmetirom

• Pregnant women. Full stop.
• Breastfeeding women.
• Women with decompensated cirrhosis (Child-Pugh B or C); the drug has not been studied in this group and is not indicated.
• Women with active hepatitis B or C co-infection requiring treatment; drug interactions and compounding liver stress need individual assessment.
• Women taking medications that significantly affect bile acid homeostasis without careful monitoring of drug levels and liver enzymes.

Women in perimenopause or postmenopause are not excluded; this group is specifically worth considering given the hormonal drivers of their MASH risk.

Safety Profile: What the Clinical Data and Label Show

Common Side Effects

In MAESTRO-NASH, the most common adverse events with resmetirom versus placebo were:

• Nausea: 26% (80 mg) and 33% (100 mg) versus 14% placebo.
• Diarrhea: 28% and 32% versus 18% placebo.
• Vomiting: 8% and 11% versus 4% placebo.

These gastrointestinal effects were predominantly mild to moderate and most frequent in the first four to eight weeks of treatment. They resemble the GI tolerability pattern seen with GLP-1 receptor agonists, which many women on this site may already be familiar with from semaglutide or tirzepatide use.

Liver Enzyme Changes

A small percentage of patients on resmetirom experienced transient elevations in liver enzymes. The label recommends baseline liver function testing and monitoring at clinically indicated intervals. Women with pre-existing liver enzyme elevation from MASH itself will have higher baseline values, so the monitoring protocol needs to distinguish treatment-related change from disease progression.

Thyroid Monitoring

Because resmetirom acts at the thyroid receptor, baseline TSH measurement is required. If you are on levothyroxine, your TSH may need rechecking at 4 to 6 weeks after starting resmetirom. Drug-drug interactions between resmetirom and levothyroxine have been flagged in the prescribing information and reflect the overlapping hepatic metabolism pathway. This interaction is particularly relevant for women, who carry the majority of the thyroid disease burden.

Statin Interactions

Resmetirom inhibits hepatic transporters involved in statin clearance, specifically OATP1B1 and OATP1B3. The FDA label includes specific dose caps for co-administered statins: for example, simvastatin doses above 20 mg daily are not recommended when taken alongside resmetirom. Given that many women with MASH also have dyslipidemia and are on statins, this interaction is likely to be clinically common rather than theoretical.

Post-Market Surveillance Requirements

Because the FDA used accelerated approval, Madrigal Pharmaceuticals is required to conduct confirmatory trials demonstrating hard clinical outcomes. The ongoing MAESTRO-NASH OUTCOMES trial is the vehicle for this. The FDA retains the authority to withdraw approval if confirmatory evidence does not arrive or if the confirmatory trial fails to demonstrate clinical benefit. Women starting resmetirom now should understand they are in a treatment field where the surrogate-endpoint evidence is strong but the long-term outcomes data are still maturing.

Ongoing Questions and Evidence Gaps for Women

Several things we do not yet know are worth naming explicitly:

Sex-stratified efficacy data. MAESTRO-NASH enrolled roughly equal numbers of women and men, but sex-disaggregated response rates are not available in the primary publication. Hormonal status at enrollment (premenopausal versus postmenopausal) was not reported as a subgroup. This is a meaningful omission for a disease where estrogen biology is a known driver.

PCOS-specific data. No dedicated trial has examined resmetirom in women with PCOS-associated MASH. This population may respond differently given the androgen and insulin resistance milieu.

Interaction with menopausal hormone therapy. Women who use estrogen-based MHT for perimenopausal symptoms and who also have MASH are a real clinical scenario. Whether MHT affects resmetirom pharmacokinetics, or whether resmetirom affects hepatic estrogen metabolism, is not addressed in the current label or published literature.

Long-term bone and cardiovascular safety. Thyroid receptor agonism at any level raises theoretical questions about bone turnover and cardiac rhythm over years of use. The bone and cardiac safety data from MAESTRO-NASH were reassuring at 52 weeks, but long-term data in postmenopausal women, who already carry higher fracture and cardiovascular risk, are not yet available.

As The Menopause Society has noted in its metabolic health guidance, menopausal women with fatty liver disease represent an underserved population where clinician awareness and referral rates remain low. Resmetirom's arrival changes the treatment calculus, but only if women are actually diagnosed and offered the drug.

Accessing Rezdiffra: US vs Europe Practical Guidance

In the United States, Rezdiffra is available by prescription for eligible patients (F2-F3 MASH confirmed by biopsy or validated non-invasive scoring). Madrigal has a patient assistance program for those without adequate insurance coverage.

In Europe, the drug is not yet approved. Women in EU member states seeking treatment should ask their hepatologist about enrollment in the ongoing MAESTRO-NASH OUTCOMES trial or other open-label extension studies. Named-patient access programs exist in some countries for compassionate use, but availability varies by national regulatory framework.

Women in Canada, Australia, and the UK are in a similarly early position: no marketing authorization has been granted as of early 2025 in those jurisdictions. Australia's TGA and the UK's MHRA are monitoring the EMA rolling review.